erlotinib krka
krka, d.d., novo mesto - erlotinibas - plėvele dengtos tabletės - 100 mg - erlotinib
erlotinib krka
krka, d.d., novo mesto - erlotinibas - plėvele dengtos tabletės - 150 mg - erlotinib
sunitinib g.l. pharma
g.l. pharma gmbh - sunitinibas - kietosios kapsulės - 12,5 mg - sunitinib
sunitinib g.l. pharma
g.l. pharma gmbh - sunitinibas - kietosios kapsulės - 25 mg - sunitinib
sunitinib g.l. pharma
g.l. pharma gmbh - sunitinibas - kietosios kapsulės - 50 mg - sunitinib
sunitinib zentiva
zentiva k.s. - sunitinibas - kietosios kapsulės - 12,5 mg - sunitinib
sunitinib zentiva
zentiva k.s. - sunitinibas - kietosios kapsulės - 50 mg - sunitinib
calquence
astrazeneca ab - acalabrutinib - leukemija, limfocitinė, lėtinė, b-ląstelė - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukemija, plaukuotoji ląstelė - antinavikiniai vaistai - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
sunitinib accord
accord healthcare s.l.u. - sunitinibas - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antinavikiniai vaistai - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.